# A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients

> **NCT06771245** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 606 (estimated)

## Conditions studied

- Mild-to-moderate Essential Hypertension

## Interventions

- **DRUG:** SYH9056
- **DRUG:** Levamlodipine
- **DRUG:** Valsartan
- **DRUG:** SYH9056 placebo
- **DRUG:** Levamlodipine placebo
- **DRUG:** valsartan placebo

## Key facts

- **NCT ID:** NCT06771245
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 606 (ESTIMATED)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06771245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06771245, "A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06771245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*